Nuveen Asset Management LLC reduced its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 12.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,202,378 shares of the medical research company’s stock after selling 325,957 shares during the quarter. Nuveen Asset Management LLC owned about 1.15% of Iqvia worth $312,474,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Sawtooth Solutions LLC purchased a new stake in shares of Iqvia in the second quarter worth approximately $1,018,000. Whittier Trust Co. raised its stake in shares of Iqvia by 17.4% in the second quarter. Whittier Trust Co. now owns 64,256 shares of the medical research company’s stock worth $9,117,000 after purchasing an additional 9,525 shares during the last quarter. Aviva PLC raised its stake in shares of Iqvia by 295.2% in the first quarter. Aviva PLC now owns 261,469 shares of the medical research company’s stock worth $28,202,000 after purchasing an additional 195,309 shares during the last quarter. Guggenheim Capital LLC raised its stake in shares of Iqvia by 213.5% in the first quarter. Guggenheim Capital LLC now owns 50,656 shares of the medical research company’s stock worth $5,464,000 after purchasing an additional 34,498 shares during the last quarter. Finally, Advisor Group Holdings Inc. purchased a new stake in shares of Iqvia in the first quarter worth approximately $3,764,000. 88.65% of the stock is currently owned by institutional investors and hedge funds.
Shares of Iqvia stock traded down $0.67 during trading hours on Wednesday, reaching $164.04. The company had a trading volume of 53,972 shares, compared to its average volume of 1,434,445. Iqvia Holdings Inc has a one year low of $81.79 and a one year high of $170.51. The business has a fifty day simple moving average of $160.28 and a 200 day simple moving average of $140.58. The company has a debt-to-equity ratio of 2.04, a current ratio of 1.10 and a quick ratio of 1.09. The firm has a market cap of $31.50 billion, a PE ratio of 242.34, a price-to-earnings-growth ratio of 2.82 and a beta of 1.33.
Iqvia (NYSE:IQV) last posted its quarterly earnings results on Wednesday, July 22nd. The medical research company reported $1.18 EPS for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.12. Iqvia had a return on equity of 17.90% and a net margin of 1.21%. The firm had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company earned $1.53 earnings per share. On average, research analysts forecast that Iqvia Holdings Inc will post 5.72 EPS for the current year.
In related news, insider Ari Bousbib sold 69,120 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $161.66, for a total value of $11,173,939.20. Following the sale, the insider now owns 721,155 shares in the company, valued at $116,581,917.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ronald E. Bruehlman acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was acquired at an average price of $159.94 per share, for a total transaction of $1,599,400.00. Following the transaction, the insider now directly owns 16,751 shares of the company’s stock, valued at approximately $2,679,154.94. The disclosure for this purchase can be found here. Insiders sold 3,034,251 shares of company stock valued at $483,026,134 over the last ninety days. Corporate insiders own 1.40% of the company’s stock.
IQV has been the subject of several analyst reports. TheStreet downgraded Iqvia from a “b-” rating to a “c” rating in a research note on Wednesday, July 22nd. Zacks Investment Research raised Iqvia from a “sell” rating to a “hold” rating and set a $167.00 price target for the company in a research report on Monday, July 27th. Robert W. Baird increased their price target on Iqvia from $156.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday, July 23rd. Bank of America increased their price target on Iqvia from $145.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Finally, Mizuho increased their price target on Iqvia from $153.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Iqvia has a consensus rating of “Buy” and a consensus target price of $165.11.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: What is insider trading?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.